The purpose of the trial is to compare the effect of adding the new drug to usual treatment versus adding a placebo. Patients receive a combination of chemotherapy that may include irinotecan, oxaliplatin, paclitaxel albumin-bound, gemcitabine, fluorouracil, and calcium folinate hydrate. The oral study medication or the placebo is taken each day, while the chemotherapy drugs are given through an IV infusion on scheduled days.

Participants are randomly assigned to one of the two groups and neither they nor the doctors know which group they are in. Treatment cycles are repeated every few weeks, with regular visits for drug administration, blood tests, and imaging scans to check the tumor. The study continues until the disease progresses, side effects require stopping treatment, or a predefined period of follow‑up is completed.

The purpose of the trial is to determine whether survodutide can lower the risk of serious liver‑related events and death in people with compensated cirrhosis due to NASH/MASH. Participants will receive the study injection each week for about a year and will attend regular clinic visits for safety checks, blood tests, and imaging. The main outcome looks at the time until the first occurrence of any major event such as liver transplant, death, hepatic decompensation (a worsening of liver function), a rise in the MELD score (a number that reflects how well the liver works) to 15 or higher, or the development of CSPH (high blood pressure in the vessels of the liver). Additional measurements include changes in the ELF score (a blood test that indicates liver scarring), body weight, blood sugar levels, and liver stiffness assessed by FibroScan (an ultrasound that measures how firm the liver is) and MRE (a type of MRI scan for the same purpose). Blood tests will also track liver enzymes AST and ALT, which rise when liver cells are damaged.

The main goal of the trial is to find out whether survodutide can improve liver health better than the placebo. “Improving liver health” means the disease may disappear without the scar tissue getting worse, and the scar tissue may become less severe. Terms such as MRI refer to a scan that uses magnets to create detailed pictures of the liver, while VCTE is a quick test that measures how stiff the liver is, which helps doctors see how much scarring is present.

Participants will receive the weekly injection for about one year and will attend regular visits where blood samples are taken, weight is measured, and imaging tests such as MRI and VCTE are performed. After the treatment period, they will continue to be followed for several more months to monitor long‑term safety and any changes in liver condition.

The purpose of the study is to find out if depemokimab works better than placebo in treating people with this lung disease who have a type of inflammation called Type 2 inflammation. The study will look at whether the medication can reduce the number of times symptoms suddenly get worse, which doctors call exacerbations. These are times when breathing problems become much worse and may need treatment with antibiotics or steroid pills, or sometimes even a visit to the emergency room or hospital.

During the study, people will receive treatment for up to 104 weeks, which is about two years. The doctors will check how often breathing problems get worse, how long it takes before problems get worse, and how the disease affects daily life and breathing symptoms. The study will compare results between people receiving depemokimab and those receiving placebo to see if the medication helps reduce flare-ups and improves quality of life for people with this lung condition.

The purpose of the study is to find out if felzartamab works better than placebo in treating this type of inflammation in transplanted kidneys. The study will also look at whether the medication is safe and how it affects kidney function over time. The inflammation is identified through a kidney biopsy, which is a procedure where a small piece of kidney tissue is examined under a microscope. The study will check if the medication can reduce or eliminate the inflammation seen in the biopsy and whether it can help maintain or improve how well the transplanted kidney is working.

The study is divided into different parts and will last for about one year for each participant. During this time, participants will receive the study medication or placebo through infusions at scheduled visits. Throughout the study, participants will have regular check-ups that include blood tests, urine tests, measurements of vital signs like blood pressure and heart rate, and tests to check how well the kidney is functioning. Another kidney biopsy will be performed during the study to see if there are any changes in the inflammation. The study will also monitor for any side effects or unwanted reactions to the medication.

The purpose of the study is to evaluate how effective Felzartamab is in treating patients with active or chronic active AMR. Participants in the study will receive either Felzartamab or a placebo through an intravenous infusion, which means the medication is given directly into a vein. The study will last for a period of up to 12 months, during which participants will have regular visits to monitor their health and the effects of the treatment.

In addition to Felzartamab, the study will also use a Saline Solution for infusion, which is a simple saltwater solution often used in medical treatments. The study aims to gather information on the safety and effectiveness of Felzartamab in improving the condition of kidney transplant recipients experiencing AMR. Participants will be closely monitored throughout the study to ensure their well-being and to collect data on how the treatment affects their condition.

The purpose of the study is to determine whether weekly injections of the drug improve nerve symptoms compared with the placebo. Participants will receive an injection each week for several months and will attend regular visits where doctors will check nerve function using a questionnaire called the mTCNS (a score that rates how severe the nerve problems are). Other questionnaires will also be used, such as the Norfolk QoL-DN (a quality‑of‑life survey for nerve disease), the clinESSDAI and ESSDAI (measures of overall disease activity), the NPQ (a questionnaire about pain), a NRS rating for difficulty thinking, and patient‑ and clinician‑rated impression scales (PGIS, PGIC, CGIS, and CGI). Fatigue will be measured with the FACIT-Fatigue questionnaire.

Throughout the study, safety will be monitored by checking vital signs, heart rhythm, blood tests, and any side effects that may occur. Participants will have the opportunity to report any adverse events, and the study team will evaluate the seriousness of any findings. The overall design allows comparison of the drug’s effect with the placebo while keeping participants and investigators unaware of which treatment is being given.

Participants in the study will take an oral tablet. Some will receive different doses of KT-621, while others will receive a placebo. To ensure the results are fair, the study is double blind, meaning neither the participants nor the researchers know which specific treatment is being administered at any given time. The study is organized into different groups that receive their assigned medication simultaneously to compare how well the drug works and to monitor its safety profile.

Participants are randomly assigned to receive either belumosudil tablets taken by mouth or one of the comparator medicines chosen by their doctor. The study lasts about 24 weeks, during which regular clinic visits are scheduled to check symptoms, perform blood tests, and assess overall health. Researchers look at the overall response rate, which means the percentage of people whose disease shows improvement, using standard doctor‑approved guidelines (NIH consensus response criteria). Systemic therapy refers to medicines that work throughout the whole body, and any need for new systemic treatment, relapse of the underlying disease, or death is recorded.

Throughout the trial, safety is closely monitored; blood samples are taken to measure drug levels and to watch for side effects. Participants can stop the study at any time if they experience problems. The information gathered will help determine whether belumosudil works better and is safe for people with this condition.

The main goal is to see whether adding PVEK to the standard pair of Venetoclax and Azacitidine can increase the rate of complete remission and help patients live longer, measured as overall survival. Participants will receive the medicines in regular cycles over several months, with clinic visits for dosing, blood tests, and health questionnaires. The study is divided into two parts: an early stage that looks primarily at remission rates, and a later stage that also compares how long patients survive.

Throughout the trial, doctors will watch for side effects and any changes in how the disease behaves. Patients will have routine check‑ups, lab work, and imaging as needed to ensure safety and to track the disease. After the treatment period, follow‑up visits continue for a period to monitor long‑term outcomes and quality of life.

The purpose of the study is to see which treatment more often gets the level of LDL-C (the laboratory name for bad cholesterol) below 55 mg/dL after about three months. Participants will be checked at the start, after 12 weeks and again after a year. Blood samples will be used to measure the amount of cholesterol‑carrying proteins such as Apo-B100 and Apo-A1, as well as apolipoprotein (a) and a marker of inflammation called hs-CRP. Simple questionnaires will also be given to assess mood using the HADS-D score and to evaluate psychological flexibility.

During the trial participants will take the assigned tablets once each day and attend the three scheduled visits where a nurse or doctor will draw a small amount of blood, ask the questionnaires and check for any side effects. The study will continue for about one year, after which the collected information will be used to compare the two treatment approaches.

The purpose of the study is to determine whether the experimental drug, alone or together with the blood‑vessel‑blocking drug, can improve overall survival compared with the standard pill combination plus the blood‑vessel‑blocking drug.

Participants are randomly placed into one of three groups: one group receives the experimental drug alone, a second group receives the experimental drug combined with the blood‑vessel‑blocking drug, and a third group receives the standard pill combination together with the blood‑vessel‑blocking drug. Treatments are given in repeated cycles, and participants have regular clinic visits for check‑ups, blood tests, imaging scans, and monitoring for side effects. The study continues until the disease progresses or the treatment can no longer be tolerated.

The purpose of the study is to compare how well the new oral tablet, alone or combined with standard chemotherapy, works against standard chemotherapy alone in controlling the cancer. Participants are randomly assigned to one of the three groups and receive treatment in repeating 28‑day cycles. During the study, regular doctor visits, imaging scans, blood tests, and quality‑of‑life questionnaires are performed to track disease status and any side effects. Treatment continues until the cancer grows, side effects become unacceptable, or the study ends after about two years.

Randomly assigned means the chance decides which group a participant joins, helping to keep the comparison fair. Open‑label indicates that both the medical team and participants know which treatment is being given. A cycle refers to a set period of treatment followed by a short rest, typically one month. Progression means the cancer is getting larger or spreading, which doctors watch for using standard imaging methods.

The purpose of the study is to see whether adding Rinatabart Sesutecan can keep the cancer from growing for a longer time compared with the usual treatment alone. Participants are randomly placed into one of the two groups after completing their second‑line chemotherapy, then they receive the assigned maintenance therapy for several months while doctors monitor their health through regular clinic visits and scans.

Progression‑free survival means the period during which the cancer does not get worse. Doctors use a set of rules called RECIST to measure whether tumors have grown or shrunk on imaging tests. To understand how the treatments affect overall well‑being, participants also complete a questionnaire known as the EORTC QLQ‑C30, which asks about symptoms, daily activities, and overall quality of life.

The purpose of the study is to find out whether taking the study drug in the evening can improve heart‑related and metabolism measures and help reset the body’s internal clock. Participants are randomly assigned to receive either the active medication or the placebo for several weeks, then after a short break they switch to the other option, without knowing which they are taking. During the study, they will have regular visits for simple tests such as blood draws, a scan that checks the amount of fat in the liver (hepatic lipid content), blood pressure checks while lying down, and basic blood counts that show inflammation. Terms like “cardio‑metabolic” refer to the heart and metabolism together, while “chronobiology” means the daily rhythm that controls many body functions.

The purpose of the study is to find out whether PIPE-791 can preserve breathing ability better than the placebo. Participants will take the study medication or placebo every day for about six months, with regular visits to check health, report any side effects, and undergo simple breathing tests. One of the key breathing tests measures forced vital capacity (FVC), which is the amount of air a person can push out of the lungs after taking a deep breath; this helps doctors see how the lungs are working. At selected visits, a special detailed X‑ray scan called HRCT will be used to look at the amount of scarring in the lungs. The study follows participants for the full treatment period to monitor safety and how well the drug works.

The purpose of the study is to evaluate the safety of two different dose levels of the experimental medicine compared with the standard treatment. Participants are randomly assigned without knowing which medication they receive (double‑blind) and are followed for about one year after the transplant. During this time, doctors monitor for any side effects, serious side effects, or events of special interest, and they also track how well the transplanted kidney works. The study involves a series of clinic visits where blood samples are taken and routine health checks are performed, but no complex procedures are required.

The purpose is to compare how well the cancer is controlled when the experimental drug is added to chemotherapy versus chemotherapy alone. After enrollment, participants are randomly assigned to one of the two groups, take the study medication daily in tablet form, and undergo regular clinic visits for treatment cycles and safety checks. The study continues until the disease progresses, the participant stops treatment, or the study ends, with follow‑up visits to monitor overall health and any side effects.

Participants are randomly assigned to receive either Sapablursen or the placebo, and neither the participants nor the study staff know which treatment is given (double‑blind). Throughout the study, regular blood tests are performed to measure the hematocrit level (the proportion of red blood cells in the blood). If the hematocrit rises above a certain level, a phlebotomy—a simple procedure where a small amount of blood is drawn to lower the count—may be needed. Researchers also ask participants to complete short questionnaires about fatigue and other symptoms to see how the treatment affects daily feeling. The trial lasts roughly 32 weeks, with visits scheduled at regular intervals to monitor safety, any side effects, and overall health.

The purpose of the study is to evaluate how effective imlunestrant is compared to these standard treatments in preventing the return of breast cancer in patients who have already received two to five years of standard endocrine therapy. Endocrine therapy is a treatment that helps to stop or slow the growth of cancer by blocking the body’s natural hormones. Participants in the study will be randomly assigned to receive either imlunestrant or one of the standard treatments. The study will monitor participants over a period of time to see how well the treatments work in preventing cancer from coming back.

Throughout the study, participants will receive regular check-ups and assessments to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on whether imlunestrant can offer a better option for patients with this type of breast cancer, potentially improving outcomes and reducing the risk of cancer recurrence. The study will also look at the overall health and quality of life of participants while they are receiving treatment.

The study will use different combinations of these medications. Some participants will receive both mirikizumab and tirzepatide, while others will receive mirikizumab and a placebo. Both medications are given as injections under the skin, except in some cases where mirikizumab may be given through a vein. The treatment will continue for 52 weeks, which is approximately one year.

The study will measure how well the medications work together to achieve three main goals: reducing Crohn’s Disease symptoms, healing the inside of the digestive tract, and helping participants lose weight. The amount of tirzepatide used in the study may be adjusted up to 15 milligrams, depending on how well it is tolerated.

The treatment being studied involves a combination of two medications: MK-1084 and pembrolizumab. Pembrolizumab is also known by the brand name KEYTRUDA and is given as an infusion, which means it is delivered directly into the bloodstream through a vein. MK-1084 is taken as a tablet. Some participants in the study will receive pembrolizumab with MK-1084, while others will receive pembrolizumab with a placebo, which looks like the real medication but does not contain any active ingredients. The purpose of the study is to compare the effectiveness of these two treatment combinations.

Participants in the study will receive their assigned treatment and will be monitored over a period of time to see how their cancer responds. The study will look at how long participants live without their cancer getting worse, known as progression-free survival, and overall survival, which is the length of time participants live after starting the treatment. The study will also track any side effects experienced by participants and how the treatment affects their quality of life. This information will help researchers understand the potential benefits and risks of the new treatment combination for people with this specific type of lung cancer.

The purpose of the study is to continue providing benralizumab to individuals who have already shown benefit and to monitor its long‑term safety and how well it is tolerated. After completing the earlier trial, participants will receive regular injections of the medication for an extended period, with scheduled clinic visits where doctors check for any side effects or health changes and collect safety information. The study will end several weeks after the last dose is given.

The purpose of the study is to find out whether JNJ-78934804 can bring participants to a state of clinical remission (no noticeable symptoms) and an endoscopic remission (no visible inflammation when doctors look inside the gut with a camera) by week 48. Participants will receive a series of injections over about a year and will attend regular clinic visits where doctors check health, assess symptoms and may perform simple imaging to look at the gut. Throughout the study, neither the participants nor the treating doctors know which medication is being given, helping to keep the results unbiased.

The main goal of the study is to see whether the new combination works better and is safe compared with the single drug. Participants will receive their assigned injection at regular visits over about one year, and they will come to the clinic for check‑ups, blood tests, and questionnaires about symptoms. The study is double‑blind, meaning neither the participants nor the doctors know which treatment is being given, to keep the results unbiased.

The key result the researchers are looking for is clinical remission at week 48, which means the person’s symptoms have cleared enough that they no longer need daily medication for the disease. Throughout the trial, safety will be monitored by checking for any side effects or changes in health.

The purpose of the study is to determine whether nerandomilast can more effectively delay death or disease worsening compared with the placebo.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year. During this time, they will attend regular clinic visits where doctors will check skin thickness, lung function (including a test called FVC that measures how much air can be forced out of the lungs), physical ability, and overall health. The study will track any serious health events, changes in symptoms, and overall survival throughout the treatment period.

Participants in the study will be assigned to receive either muvalaplin, which is taken as an oral tablet, or a placebo. This is a randomized study, meaning the treatment assigned is determined by chance, and it is double-blind, so neither the participants nor the researchers know which treatment is being given during the trial. The study will monitor how the medication affects the risk of experiencing major heart events over time.

The study is designed to continue treatment for patients who have already participated in previous research with rocatinlimab. Participants will receive either rocatinlimab or placebo through injections under the skin. This is a long-term study that will monitor how well patients maintain improvement in their skin condition and any side effects that may occur during treatment.

The research will track various aspects of the skin condition, including changes in skin appearance, itching severity, and overall symptoms. The study will particularly focus on monitoring the safety of the treatment by recording any side effects and checking laboratory test results and vital signs throughout the treatment period.

The purpose of the study is to see how each medication changes the amount of a blood protein called serum transthyretin, which carries vitamin A and thyroid hormone and can reflect disease activity.

Participants will take one of the medicines for about four weeks, during which blood samples are collected to measure protein levels, then they will switch to the other medicine for another four‑week period with similar testing. This “crossover” design lets each person serve as their own comparison, providing information on how the two drugs affect the protein levels over short treatment periods.

During the trial, participants will take the study medication once daily for about 24 weeks. They will attend regular clinic visits where blood samples are drawn to measure hormone levels and safety checks are performed. The study follows a straightforward schedule of visits and tests, allowing researchers to observe changes in hormone levels over time without requiring any invasive procedures.

The purpose of the study is to determine whether ALKS 2680 can reduce daytime sleepiness in adults with Narcolepsy Type 1. Participants will be randomly assigned to receive either the study drug or a placebo for about twelve weeks. During the study, they will complete a questionnaire called the Epworth Sleepiness Scale that asks how likely they are to fall asleep in everyday situations, and they will take a short test called the Maintenance of Wakefulness Test that measures how long they can stay awake when asked to do so. Their episodes of cataplexy will also be recorded each week.

Throughout the trial, researchers will monitor participants for any side effects and will collect the questionnaire and test results to evaluate the safety and effectiveness of the medication. The collected information will help decide if the drug provides a beneficial option for managing the symptoms of this sleep disorder.

The purpose of the study is to find the optimal dose for a later study and to determine whether the test cream works the same way as the reference cream, a concept known as bioequivalence.

Participants will have each cream applied to a small area of skin. A tiny device using open flow microperfusion will gently collect fluid from just beneath the skin surface to measure how much medication reaches the skin over time. These measurements, called pharmacokinetic data, show the drug’s concentration at different times after application. The study lasts for about a day of monitoring after each application, with a short visit schedule for the volunteers.

The purpose of the study is to evaluate the safety and how the drug behaves in the body. Participants receive a single dose of either the study drug or the comparison solution, followed by several additional doses over a number of weeks. During this time, regular check‑ups, blood tests, and heart rhythm recordings (electrocardiogram) are performed to watch for side effects and to measure drug levels. The trial also examines whether the treatment changes the amount of a protein called C‑peptide, which reflects the pancreas’s remaining ability to produce insulin.

The main goal of the trial is to determine whether the new combination is safe and works better than current therapies. Participants will receive the assigned medicines by IV infusion in repeated cycles, with regular hospital visits for the infusions and for medical checks. Throughout the study, doctors will look for signs that tumors shrink, known as objective response, and will track how long patients live, referred to as overall survival.

After random assignment to either the experimental group or the standard‑care group, treatment continues for several weeks while imaging scans, blood tests, and questionnaires are used to assess tumor size, side effects, and quality of life. The study also measures how long the disease stays under control without getting worse, called progression‑free survival, before participants are followed for long‑term survival outcomes.

The purpose of the trial is to see whether adding the study drug to standard treatment leads to greater overall improvement in symptoms after six weeks. Volunteers are assigned to one of the two groups by chance in a double‑blind manner, meaning neither the participants nor the study staff know who receives the active substance. Over the six‑week period, participants will attend regular visits where simple questionnaires and brief health checks are completed to track changes in mood, anxiety, daily functioning, and overall quality of life. After the treatment phase, participants will have a final follow‑up visit to assess any lasting effects.

The aim of the study is to evaluate the safety and tolerability of long‑term use of this medication. Participants who have previously taken part in an earlier trial will continue to receive the inhaled powder and will be followed for up to two years. During this time they will attend regular clinic visits where simple checks such as blood tests, heart rhythm monitoring (ECG), measurement of oxygen use, and basic physical examinations are performed. The study also includes a group receiving placebo for comparison.

Throughout the study, participants will undergo a short walking test (6MWD) to see how far they can walk in six minutes, and lung function tests that measure the amount of air they can force out (FVC) and the speed of airflow (FEV1). Blood samples will be taken to check levels of a heart‑stress marker (NT-proBNP). These assessments help researchers understand how the medication affects breathing ability, heart strain, and overall health over the long term.